[1]
M. Paoletti, A. Marcellusi, J. Yang, and F. S. Mennini, “Cost-effectiveness of IMI/CIL/REL for the treatment of carbapenem non-susceptible Gram-negative bacterial infections”, Grhta, vol. 10, no. 1, pp. 18–28, Apr. 2023.